← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Ship Of Theseus, Llc
Eagleville, PA
$3,729,938
Total funding
6
Grants
Funding over time
peak $2.2M · FY2021–25$2.5M$1.9M$1.3M$625K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,729,938 · 6
By mechanism
R44$1,770,171 · 1
R61$457,450 · 1
R33$443,800 · 1
R41$399,739 · 1
N43$365,689 · 1
R43$293,089 · 1
Investigators at Ship Of Theseus, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Stimulant for stem cell expansion in vivo to speed recovery of neutropenia secondary to chemotherapy and stem cell transplant$1,770,171
R44 · FY2025 · HL
Preclinical development of a nuclear-targeting biologic that safely increases stem cell expansion in vivo to accelerate recovery from neutropenia after chemotherapy and bone marrow transplant$457,450
R61 · FY2022 · HL
Preclinical development of a tandem CART / HSC transplantation platform for hematologic malignancies$399,739
R41 · FY2025 · CA
AN INSIDE OUT APPROACH THAT REPROGRAMS WOUND TISSUE TO ACCELERATE CHRONIC WOUND HEALING IN AGING POPULATIONS$365,689
N43 · FY2022 · DA
Stimulant for stem cell expansion in vivo to speed recovery of neutropenia secondary to chemotherapy and stem cell transplant$293,089
R43 · FY2021 · HL
Preclinical development of a nuclear-targeting biologic that safely increases stem cell expansion in vivo to accelerate recovery from neutropenia after chemotherapy and bone marrow transplant$230,300
R33 · FY2023 · HL
Preclinical development of a nuclear-targeting biologic that safely increases stem cell expansion in vivo to accelerate recovery from neutropenia after chemotherapy and bone marrow transplant$213,500
R33 · FY2024 · HL